Palmetto INFUSION

MRN:_____

Phone: 1-800-809-1265 Fax: 1-866-872-8920

DOB: _____

Plan of Treatment for Uplizna™ (Inebilizumab-cdon)

NOTE: *We may require a detailed Letter of Medical Necessity or clinical supporting documentation (depending on diagnosis), to be able to verify eligibility and payment for this treatment through Medicare and/or other insurance plans.*

1. Patient Name: _____Height (inches): _____Weight (lbs):_____

2. Allergies: _____

3. Diagnosis: ☐ Primary ICD-10 Code: G36.0 Diagnosis description: Neuromyelitis optica

☐ Secondary ICD-10 Code: _____Diagnosis description: _____

4. Pre-medications: ☐ None *OR* *Administered 30 minutes prior to infusion as selected:*

Acetaminophen: ☐ 1000 mg PO ☐ 650 mg PO ☐ 500 mg PO ☐ 325 mg PO	Diphenhydramine: ☐ 25 mg PO, ☐ 50 mg PO, ☐ 25 mg IVP, ☐ 50 mg IVP or Fexofenadine ☐ 60mg or ☐ 180 mg, ☐ Cetirizine 10 mg, ☐ Loratadine 10 mg Methylprednisolone ☐ 80 mg IVP ☐ 125 mg IVP or other _____mg IVP Famotidine: ☐ 20 mg PO, ☐ 40 mg PO, ☐ 20 mg IVP, ☐ 40 mg IVP

Pre-medicate with other: _____

5. Orders:

Uplizna™ 300 mg IV to infuse per protocol via pump.

6. Frequency:

☐ **Induction dose**: Uplizna 300 mg IV to be infused over 90 minutes at 0 week and 2 weeks.

☐ **Maintenance dosing**: Uplizna 300 mg IV every 6 months (24 weeks)

*Maintenance dosing is scheduled 6 months from initial 0 week dosing.

Post infusion monitoring as per protocol or as suggested in product information of 1 hour

Special orders: _____

_____

If adverse drug reaction occurs, utilize the ADVERSE DRUG REACTION GUIDELINES

8. Physician's Signature: _____/ _____Date: _____

(Dispense as written) (Substitution permitted)

No Stamp Signatures

Printed Physician's Name with Credentials: _____NPI: _____

9. Fax updated supporting clinical MD notes with each order renewal or change in orders

Infusion order forms and Adverse Drug Reaction Guidelines are available at www.palmettoinfusion.com

Revised 5/25/18

Palmetto INFUSION

MRN:_____

Phone: 1-800-809-1265 Fax: 1-866-872-8920

DOB: _____

Plan of Treatment for Uplizna™ (Inebilizumab-cdon)
Guidelines for Prescribing
(Required documentation with all initial referrals)

Patient Name: _____ Referral Date:_____

___ Include signed and completed **Plan of Treatment**. *(MD must complete sections 1-9)*
(Infusion order forms & Standard Adverse Reactions orders are available at www.palmettoinfusion.com under Agency/MD tab)

___ Include patient demographic information and insurance information. (Copy of insurance cards if available)

___ **Supporting clinical MD notes to include any past tried and/or failed therapies, intolerance, outcomes or contraindications to conventional therapy. Include anti-aquaporin-4 (AQP4) antibody positive lab results and/or tests to support diagnosis.**

___ **Include Pre-Screening Requirements:**
___ Hepatitis B Surface Antigen
___ Tuberculosis Screening
___ Quantitative Serum Immunoglobulins

___ Other as requested: _____

_____

_____

_____

_____

_____

_____

_____

Palmetto Infusion Services will complete insurance verification and submit all required clinical documentation to the patient's insurance company for eligibility. Our office will notify you if any further information is required. We will review financial responsibility with the patient and refer them to any available Co-pay assistance as required. Thank you for the referral.

Please fax all information to 1-866-872-8920 or call 1-800-809-1265 for assistance.